• FY27 growth guidance: Glenmark is targeting revenue of ₹17,000 to ₹18,000 crore in FY27 with EBITDA margins of 21% to 22%, supported by broad-based expansion across all geographic markets.
• India and Ryaltris: The India business is expected to grow at approximately 15% and outperform the broader market, while Ryaltris has reached $100 million after 50% growth and is targeted to become a $200 million-plus brand.
• Debt and working capital: The company achieved gross debt zero in March and expects to maintain this gross debt-free status through FY27, while keeping net working capital days at 115 to 120 days.
• Branded sales target: Glenmark plans to increase its branded portfolio from 60% of revenue currently to 70% by 2030, supported by new market launches like Winlevi and recent in-licensing agreements.
• GLP-1 opportunity: The company reported encouraging initial traction for its semaglutide offering, Glipep, in India and is evaluating opportunities to enter select international markets.